Background: This document provides clinical recommendations for the diagnosis of
idiopathic pulmonary fibrosis (IPF). It represents a collaborative effort between the American …

Background Nintedanib (formerly known as BIBF 1120) is an intracellular inhibitor that
targets multiple tyrosine kinases. A phase 2 trial suggested that treatment with 150 mg of …

Background: In 2002 the American Thoracic Society/European Respiratory Society (ATS/ERS)
classification of idiopathic interstitial pneumonias (IIPs) defined seven specific entities, …

Background Preclinical data have suggested that nintedanib, an intracellular inhibitor of
tyrosine kinases, inhibits processes involved in the progression of lung fibrosis. Although the …

Background— Novel therapies have recently become available for pulmonary arterial
hypertension. We conducted a study to characterize mortality in a multicenter prospective cohort of …

Background Tuberous sclerosis complex is highly variable in clinical presentation and
findings. Disease manifestations continue to develop over the lifetime of an affected individual. …

Acute exacerbation of idiopathic pulmonary fibrosis has been defined as an acute, clinically
significant, respiratory deterioration of unidentifiable cause. The objective of this …

Background HHT is an autosomal dominant disease with an estimated prevalence of at
least 1/5000 which can frequently be complicated by the presence of clinically significant …

The syndrome resulting from combined pulmonary fibrosis and emphysema has not been
comprehensively described. The current authors conducted a retrospective study of 61 …

Many patients with an idiopathic interstitial pneumonia (IIP) have clinical features that suggest
an underlying autoimmune process but do not meet established criteria for a connective …